ANA Pattern — How to Read Common Antinuclear Antibody Staining Patterns

Your ANA (antinuclear antibody) report came back with a pattern — maybe "nuclear, homogeneous," "speckled," "cytoplasmic, reticular/AMA," or something that sounds alarming like "mitotic spindle fibers." The pattern describes how and where the antibodies stained cells under a fluorescent microscope, and it is one of the most confusing parts of any lab report. This page helps you find your exact pattern and understand what it may suggest — and what to confirm next.

The one idea that explains this whole page: the pattern shows where the staining occurred, not what disease you have. It may suggest which specific antibody to confirm next — it does not identify the antibody or diagnose a disease by itself. Read it together with your titer and, above all, your symptoms.

At a glance

• Two things are reported together: titer and pattern. Titer = the endpoint dilution (a semiquantitative estimate of how much); pattern = where and how the antibodies stained.
• The pattern may suggest a follow-up test, not a diagnosis — when the clinical context supports it (anti-dsDNA, anti-centromere, and so on). It does not determine automatically which test is ordered.
• A pattern usually suggests, it does not identify. The centromere pattern is the exception, with a particularly restricted antibody target.
• A pattern only appears when the screen is positive (at 1:80 or above); a negative screen reports no pattern.
• A positive ANA happens in healthy people, including at the 1:80 screening dilution — and sometimes at high titer, as with DFS70.
• More than one pattern may be reported. Quest reports each observed pattern with its corresponding titer; interpret each pattern-titer pair separately.
• "Mitotic spindle fibers" has low predictive value for any disease — it does not point strongly toward a diagnosis, and it is not evidence that disease is absent.
• Use the exact pattern name and AC code. Similar-sounding patterns (for example, few vs multiple nuclear dots) point to very different follow-up tests.

How to read your result: titer and pattern together

Your report shows these as separate lines because they are separate results. The screen runs first; if it is positive at 1:80 or above, the lab automatically reports the pattern and its titer. If more than one pattern is seen, each is reported with its own corresponding titer — read each pattern-titer pair separately. A negative screen produces no pattern at all.

The titer is the endpoint dilution — how far the blood was diluted and still showed antibodies (reported up to 1:1,280). On Quest's current workflow 1:80 is the screening dilution, so a 1:80 result is the lowest reported and can occur in healthy people. Higher titers raise suspicion; Quest's interpretation guide describes a titer above 1:160 as high and strongly suggestive of autoimmune disease. The pattern is the shape and location of the staining, which suggests candidate antibody targets. Neither alone is the answer — a high-titer homogeneous pattern in someone with joint pain and rashes means something very different from a low-titer speckled pattern found incidentally, and some patterns (such as dense fine speckled) can be high-titer in healthy people too.

Find your pattern

Patterns are grouped by where in the cell the antibodies stain — the nucleus, the cytoplasm, or structures that appear during cell division (mitotic). The international naming system (ICAP) currently classifies 31 positive patterns, AC-1 through AC-31, plus AC-0 for no detectable staining and AC-XX for unclassified patterns; you may see an AC code on your report. This page covers the common ones. Find your exact pattern — similar-sounding names can point to very different follow-up tests.

On the speckled row: ICAP permits reporting "nuclear speckled" at the competent level as AC-4/5 grouped, and many reports do exactly that. If your report specifies an exact AC-4 (fine) or AC-5 (large/coarse), the follow-up paths diverge somewhat — bring the exact code to your clinician.

The patterns people ask about most

Mitotic spindle fibers (AC-25). The most-searched pattern, and the key fact is that it has a low positive predictive value for any disease and is found infrequently. It reflects antibodies to the machinery cells use to divide. Low predictive value means it does not point strongly toward a particular diagnosis — but it is not evidence that disease is absent. Your clinician reads it with your titer and symptoms rather than treating the name, in either direction, as an answer.

Cytoplasmic patterns. "Cytoplasmic" describes where the staining appeared — outside the nucleus — not one shared level of risk. Reticular/AMA (AC-21) suggests antimitochondrial antibodies and primary biliary cholangitis, a chronic liver condition. AC-19 can suggest antibodies relevant to SLE, antisynthetase syndrome or necrotizing myopathy; AC-20 can suggest anti-Jo-1, linked to antisynthetase syndrome and interstitial lung disease. So "cytoplasmic" is not one result — use the exact AC code to know which follow-up matters.

Dense fine speckled (DFS70, AC-2). Often discussed as reassuring, but only under three conditions together: the pattern is confirmed as a genuine DFS70 (not the newer AC-30 look-alike), anti-DFS70 is the only relevant antinuclear antibody found, and clinical suspicion is already low. The pattern alone is not enough — your clinician confirms it.

Homogeneous and speckled are the two most common nuclear patterns; see the table above for what each may suggest and the possible follow-up.

Two people, the same "speckled" pattern

Person A has a low-titer (1:80) speckled ANA found on a general work-up, with no symptoms. For her, this is often an incidental finding — a low-titer positive ANA is common in healthy people — and the clinician may decide that no additional antibody testing is warranted.

Person B has a high-titer (1:640) speckled ANA with dry eyes, joint pain, and fatigue for months. Same pattern word, very different weight: here it may prompt specific antibody testing (for example anti-SSA/SSB, anti-U1RNP), and those results with her symptoms may point toward a defined condition.

Same pattern, different meaning — titer and symptoms, not the pattern name alone, carry the weight.

What the pattern cannot tell you

It cannot diagnose a disease. The specific antibody test and your clinical picture do that.

It cannot be read without the titer and your symptoms. A pattern with no context is not interpretable.

It cannot rule autoimmune disease in or out on its own. Positive ANAs occur in healthy people; some people with autoimmune disease have negative or atypical patterns.

Common interpretation mistakes

Reading the pattern as a diagnosis. It shows where the antibodies stained and may suggest what to confirm next — it is not a named disease or an antibody identification.

Being alarmed by a dramatic-sounding pattern. "Mitotic spindle fibers" and many cytoplasmic patterns have low disease significance; the name is not the meaning.

Ignoring the titer. A result at the 1:80 screening dilution is common and often incidental; a higher titer carries more weight.

Assuming a positive ANA means lupus. ANA is positive in many conditions and in healthy people.

Questions your doctor may ask

What is the exact pattern and titer? Both are needed — "positive ANA" alone is not enough.

Do you have symptoms, and for how long? Joint pain, rashes, dry eyes, Raynaud's, and fatigue change how a pattern is weighed.

Are you taking any medications? Some drugs cause a positive ANA (drug-induced lupus), often with a homogeneous pattern.

Read together with

ANA titer — the other half of the result; read with the pattern, never alone.

Specific antibody tests — anti-dsDNA, anti-centromere, anti-SSA/SSB, anti-U1RNP, anti-Scl-70, and others the pattern points toward.

Your symptoms and history — the context that gives any pattern its meaning.

Clinical pearls

The pattern suggests candidate target antigens, which may prompt a follow-up antibody test when the clinical context supports it. Think of it as an orienting step, read with your symptoms — not an endpoint, and not an antibody identification on its own.

There is no single "strength" ranking. The centromere pattern (AC-3) is the one with a particularly restricted antibody target; most patterns suggest a follow-up test rather than a specific answer, and several mitotic and cytoplasmic patterns have low predictive value.

Use the exact AC code. Similar-sounding patterns diverge: few nuclear dots (AC-7, low predictive value) versus multiple nuclear dots (AC-6, PBC or dermatomyositis); dense fine speckled (AC-19, cytoplasmic) versus fine speckled (AC-20, cytoplasmic). "Cytoplasmic" alone is not one result.

DFS70 (AC-2) reassurance is conditional — it requires a confirmed bona fide DFS70 (not the AC-30 look-alike), monospecific anti-DFS70, and low clinical suspicion. The pattern name alone is not enough.

A positive ANA is common in healthy people, at low titer and sometimes high; the result is always read with symptoms.

In one sentence

An ANA staining pattern shows where antibodies bound on HEp-2 cells. It may suggest a follow-up test in the right clinical context, but it does not identify an antibody or diagnose a disease.

The bottom line

Your ANA report pairs a titer (a semiquantitative estimate of how much) with a pattern (where and how the antibodies stained). The pattern shows where the staining occurred and may suggest which antibody to confirm next — it does not identify the antibody or diagnose a disease on its own. The centromere pattern is the one with a tightly restricted target; mitotic spindle fibers and several other patterns have low predictive value, meaning they point weakly toward any diagnosis (not that disease is ruled out). "Cytoplasmic" is not one result — AC-21 suggests primary biliary cholangitis, while AC-19 and AC-20 suggest myositis, antisynthetase syndrome, interstitial lung disease, or SLE. Whatever the pattern, use the exact name and AC code, read it with your titer and symptoms, and bring the report to your clinician, who orders the specific antibody tests the pattern points toward.

Clinical Takeaway Start with the exact pattern name and AC code. The pattern may suggest which antibody to confirm next, but it does not identify an antibody or diagnose a condition by itself. Read it together with your titer and symptoms; your clinician decides whether a follow-up test is warranted in your clinical context.